PARP10 and neoplasm: A comprehensive study has demonstrated that inhibitors targeting MARTs (MARTi), including RBN-2397 (PARP7), OUL-35 (PARP10), and RBN-012759 (PARP14), exhibit favorable pharmacokinetic properties and effectively modulate key signaling pathways involved in tumor growth and metastasis, supporting their potential for future therapeutic application (Table 1).